Overview

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

Status:
Terminated

Trial end date:
2008-12-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety of donepezil hydrochloride (Aricept) in children with Down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. Medical tests for drug safety will be conducted at each clinic visit.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Pfizer

Treatments:

Donepezil